Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us

  • Exchange: Berlin
  • Sector: Health Care
  • Industry: Medical Equipment & Devices
  • Sub-Industry: Life Science Equipment

Spectral Medical Inc

+ Add to Watchlist

SD4:GR

0.753 EUR 0.079 9.50%

As of 02:08:09 ET on 04/24/2015.

Snapshot for Spectral Medical Inc (SD4)

Open: 0.782 Day's Range: 0.753 - 0.782 Volume: 0
Previous Close: 0.832 52wk Range: 0.154 - 0.880 1-Yr Rtn: +348.21%

Stock Chart for SD4

No chart data available.
  • SD4:GR 0.782
  • 1D
  • 1M
  • 1Y
0.832
Interactive SD4 Chart

Previous Close

No chart data available.
Interactive Chart
  • 1D
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for SD4

Current P/E Ratio (ttm) -
Estimated P/E(12/2015) -
Relative P/E vs. DAX -
Earnings Per Share (CAD) (ttm) -
Est. EPS (CAD) (12/2015) -0.0600
Est. PEG Ratio -
Market Cap (M EUR) 135.36
Shares Outstanding (M) 179.76
30 Day Average Volume 604
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 05/15/2015
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for SD4

  • Revenue
  • Net Income (M/CAD)
  • Profit Margin (%)

Company Profile & Key Executives for SD4

Spectral Medical Inc is inPhase III, seeking FDA approval for its theranostics product for the treatment of severe sepsis and septic shock. Toraymyxin is a therapeutic hemoperfusion device that removes endotoxin, which can cause sepsis, from the bloodstream. Directed by the Company's Endotoxin Activity Assay, Spectral's EUPHRATES trial is a theranostics trial in the area of sepsis.

Paul M WalkerPresident/CEOAnthony BusinskasExec VP/CFO/Secy
Debra FosterVP:Clinical Development
More Company Profile & Key Executives for SD4

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil